A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.

Fadlyana E; Rusmil K; Tarigan R; Rahmadi AR; Prodjosoewojo S; Sofiatin Y; Khrisna CV; Sari RM; Setyaningsih L; Surachman F

doi:10.1016/j.vaccine.2021.09.052

A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.

Identifier:nobleid.org/w1/20260526/1FD0CFE6

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/1FD0CFE6.svg?ark=w1%2F20260526%2F1FD0CFE6)](https://nobleid.org/work/w1/20260526/1FD0CFE6)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.

Identifier:nobleid.org/w1/20260526/1FD0CFE6

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/1FD0CFE6.svg?ark=w1%2F20260526%2F1FD0CFE6)](https://nobleid.org/work/w1/20260526/1FD0CFE6)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work